The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV)

Filter results
Date Title PDF
20/10/2021 The FDA delays its decision on Risperidone ISM®
1/09/2021 ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine
29/08/2021 ROVI informs on the evolution of the investigation of particulate matter having been seen in certain drug product vials of the Moderna COVID-19 vaccine distributed in Japan
26/08/2021 ROVI informs on the notification of particulate matter having been seen in certain drug product vials of the Moderna's COVID-19 vaccine distributed in Japan
9/08/2021 ROVI achieves second place in a worldwide sustainability rating
28/07/2021 First half 2021 results press release
13/05/2021 First quarter 2021 results press release
29/04/2021 ROVI increases its fill-finish capacity for the COVID-19 Vaccine Moderna
12/04/2021 ROVI participates in the manufacture of the active substance of Moderna’s COVID-19 vaccine
2/03/2021 Update on Doria® regulatory processes

Pages